AWAU
VRTX icon

Alliance Wealth Advisors (Utah)’s Vertex Pharmaceuticals VRTX Stock Holding History

Alliance Wealth Advisors (Utah)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$575K Sell
1,157
-553
-32% -$245K 0.11% 117
2026
Q1 		$764K Sell
1,710
-634
-27% -$296K 0.17% 93
2025
Q4 		$1.06M Sell
2,344
-554
-19% -$239K 0.23% 93
2025
Q3 		$1.13M Buy
2,898
+753
+35% +$315K 0.27% 103
2025
Q2 		$955K Buy
2,145
+572
+36% +$264K 0.23% 102
2025
Q1 		$763K Buy
1,573
+638
+68% +$297K 0.2% 114
2024
Q4 		$377K Buy
+935
New +$433K 0.1% 192

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Alliance Wealth Advisors (Utah)'s VRTX Position: Q2 2026 in Review

Alliance Wealth Advisors (Utah) reduced its Vertex Pharmaceuticals (VRTX) stake by 32% in Q2 2026, selling an estimated $245K and leaving 1,157 shares worth $575K. The position accounts for 0.11% of the portfolio, ranked #117.

Alliance Wealth Advisors (Utah) first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.13M in Q3 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Alliance Wealth Advisors (Utah) held 1,157 shares of Vertex Pharmaceuticals worth $575K as of Q2 2026.
  • Alliance Wealth Advisors (Utah) sold 553 Vertex Pharmaceuticals shares in Q2 2026, an estimated $245K.
  • Vertex Pharmaceuticals made up 0.11% of Alliance Wealth Advisors (Utah)'s portfolio in Q2 2026, its #117 holding.
  • Alliance Wealth Advisors (Utah) first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Alliance Wealth Advisors (Utah)'s Vertex Pharmaceuticals position peaked at $1.13M in Q3 2025.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Alliance Wealth Advisors (Utah)'s 13F filing for Q2 2026, filed 23 Jul 2026.